As one of the effective means of precision medicine, Nucleic Acid-based Medicines can directly act on the target genes or target mRNA and regulate the expression of the therapeutic genes from the root. The RNA-based medicines have greatly expanded the range of selectable targets of the innovative drugs, making the previously undruggable targets possible. In recent years, with the maturation of technologies for chemical modification, nucleic acids delivery and manufacturing, RNA-based Therapeutics is expanding rapidly with multiple products launch onto the market, showing increasingly prominent clinical advantage and market value. At the same time, mRNA technology has entered a rapid development phase in the context of the COVID-19 pandemic. Although the research and development is mainly focused on the field of vaccines, mRNA also great potential in immuno-therapy, protein replacement therapy, cell therapy, regenerative medicine and other fields. In Return, the xRNA Therapeutics Development and Innovation Forum will gather leaders and scientists across RNA-based medicines Innovators, leading academic centers and institutes for the discussion and case studies with the aim to facilitate the communication and partnership for the development, delivery and manufacturing of the next generation mRNA/circRNA-based Vaccines/Therapeutics and Oligonucleotide Drugs. Currently we are receiving the presentation abstracts for xRNA2025. If you'd be interested in speaking, please contact Wei Zhang at wzhang@deliver-consulting.com.